Giant supratentorial brain tumors in children: functional outcome and progression-free survival analysis.

Research Article

Open Access Gateway Saenz A. · basilotta marquez Y. · Dalton E.A. · Argañaraz R. · Mantese B.
Abstract

Introduction: This study aimed to identify factors affecting progression-free survival (PFS) in pediatric patients with giant supratentorial brain tumors (GSBT) treated with surgical excision. The secondary aim was to analyze how these same factors affected the functional outcome in the long term. Methods: We performed a retrospective, analytical, single-center cohort study. We included all pediatric patients with GSBT between January 2014 to June 2018. Patients were followed for a minimum of 24 months for the PFS and overall survival (OS) analysis. Functional Status Score (FSS) was used to assess the functional outcome. Results: We included 27 patients with GSBT, the median age was six (range 2-12), and eleven patients had a grade IV tumor. The 24-month PFS and OS were 51.85% and 74.04%, respectively. A PFS-ending event or treatment failure occurred in 13 patients. We found that patients with postoperative FFS> 16 have a worse PFS than patients with a postoperative FSS 16, and CNS infections.

S. Karger AG, Basel

 Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
View original article
PEDIATRIC NEUROSURGERY

留言 (0)

沒有登入
gif
format_indent_decrease